HAE

SEC source: 0001127602-25-014934 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,274

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 150 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024.

SEC source: 0001127602-25-014933 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,707

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 349 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.

SEC source: 0001127602-25-015070 · form4.xml · derivative · entry 2

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,732

Underlying: Common Stock · 1,732 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015070 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,816

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-015067 · form4.xml · derivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,928

Underlying: Common Stock · 6,928 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015067 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,474

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-015063 · form4.xml · derivative · entry 2

Chan Frank · CIK 0002061743 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,317

Underlying: Common Stock · 12,317 shares

Expires 2032-05-16

F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015063 · form4.xml · nonDerivative · entry 1

Chan Frank · CIK 0002061743 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,689

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-25-015061 · form4.xml · derivative · entry 2

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,626

Underlying: Common Stock · 14,626 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015061 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,998

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-015058 · form4.xml · derivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,317

Underlying: Common Stock · 12,317 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015058 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,167

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-015054 · form4.xml · derivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,396

Underlying: Common Stock · 15,396 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015054 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,935

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-015052 · form4.xml · derivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,342

Underlying: Common Stock · 46,342 shares

Expires 2032-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-015052 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,112

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-017498 · form4a.xml · derivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,626

Underlying: Common Stock · 14,626 shares

Expires 2032-05-16

F5 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 12,317 instead of 14,626. This net increase of 2,309 options will be reflected in future filings by the reporting person.

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-017498 · form4a.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,233

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 5,689 instead of 6,755. This net increase of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person.

F3 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F4 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-017492 · form4a.xml · derivative · entry 2

Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,317

Underlying: Common Stock · 12,317 shares

Expires 2032-05-16

F5 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person.

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-25-017492 · form4a.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,932

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person.

F3 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F4 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014945 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,635

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014944 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,070

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014941 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,084

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-25-014938 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.

SEC source: 0001127602-25-014934 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,751

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 150 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024.

SEC source: 0001127602-25-014933 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,796

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 349 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.

SEC source: 0001127602-25-013343 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,692

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-026473 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,373

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 124 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024.

SEC source: 0001127602-24-024136 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,807

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-023305 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,838

F1 · shares: On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-021110 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,508

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-021040 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,288

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021039 · form4.xml · nonDerivative · entry 1

Bryant Diane M · CIK 0001687544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,433

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021038 · form4.xml · nonDerivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,701

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021036 · form4.xml · nonDerivative · entry 1

Johnson Lloyd Emerson · CIK 0001708823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,240

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021037 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,433

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021035 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,664

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021034 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,179

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021033 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,680

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,306

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on July 13, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from July 13, 2021 to July 12, 2024, as certified by the Compensation Committee of the Board of Directors on Jul 24, 2024.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-020383 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,331

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-020383 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,410

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated March 13, 2024 (fully executed as of March 13, 2024).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-018160 · form4.xml · derivative · entry 3

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 104,516 shares

Expires 2024-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4.

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-018160 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 362,542

F3 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-018160 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 433,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 4

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,257

F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.92, inclusive.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 3

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,351

F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016816 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,546

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.